hVIVO (LON:HVO) Stock Price Down 46.3% – Here’s What Happened

hVIVO plc (LON:HVO) traded down 46.3% on Saturday . The company traded as low as GBX 6.50 ($0.09) and last traded at GBX 8.70 ($0.12). 83,062,000 shares traded hands during trading, an increase of 2,325% from the average session volume of 3,424,608 shares. The stock had previously closed at GBX 16.20 ($0.22).

Wall Street Analyst Weigh In

Separately, Shore Capital restated a “buy” rating on shares of hVIVO in a research note on Friday.

hVIVO Stock Performance

The company has a debt-to-equity ratio of 33.86, a current ratio of 1.61 and a quick ratio of 1.16. The stock’s 50-day moving average price is GBX 16.16 and its 200-day moving average price is GBX 18.04. The company has a market cap of £61.56 million, a P/E ratio of 3.59 and a beta of 0.97.

hVIVO (LON:HVO) last announced its earnings results on Thursday, April 10th. The company reported GBX 1.69 ($0.02) earnings per share (EPS) for the quarter. hVIVO had a net margin of 25.96% and a return on equity of 47.93%. Equities analysts anticipate that hVIVO plc will post 1.5492958 EPS for the current year.

Insider Buying and Selling

In related news, insider Yamin Mo’ Khan sold 3,062,246 shares of the business’s stock in a transaction dated Thursday, March 6th. The stock was sold at an average price of GBX 17 ($0.23), for a total value of £520,581.82 ($700,648.48). 14.03% of the stock is currently owned by company insiders.

About hVIVO

hVIVO plc operates as a pharmaceutical service and contract research company. The company is involved in testing vaccines and antivirals using human challenge clinical trials. It provides services to big pharma, biotech, government, and public health organizations. The company has a portfolio of human challenge study models for conditions, such as RSV, flu, human rhinovirus, asthma, malaria, cough, and COPD, as well as developing COVID-19 human challenge study model.